AVRO News and Press, AVROBIO Inc. From 04/07/20

The following slide deck was published by AVROBIO, Inc. in conjunction with this Read more ...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...

Patient identification for clinical trials continues; dosing temporarily paused as clinical trial sites focus on COVID-19 pandemic Essential laboratory and manufacturing activities currently uninterrupted Cash runway into Q2 2022 AVROBIO, Inc. (Nasdaq:AVRO), a leading clin...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...

AVROBIO, Inc . (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that members of its senior management team will participate at three upcoming virtual investor conferences: Guggenheim Healthcar...

The following slide deck was published by AVROBIO, Inc. in conjunction with this Read more ...

AVROBIO (NASDAQ: AVRO ): Q4 GAAP EPS of -$0.72 misses by $0.11 . More news on: AVROBIO, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

Presented positive data at the 16 th Annual WORLD Symposium ™ on AVR-RD-04 for cystinosis and AVR-RD-01 for Fabry disease, as well as early data on plato™-produced drug product and plasma enzyme activity level Received orphan drug designation from U.S. Food and Drug Adm...

AVR-RD-04 is the third AVROBIO investigational gene therapy to receive orphan status AVROBIO, Inc . (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the U.S. Food and Drug Administratio...

AVROBIO, Inc. (NASDAQ: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced Geoff MacKay, president and CEO of AVROBIO, will present at the Cowen and Company 40 th Annual Health Care Conference at 4:50 p.m. E...